| Year |
Citation |
Score |
| 2023 |
Efe G, Dunbar KJ, Sugiura K, Cunningham K, Carcamo S, Karaiskos S, Tang Q, Cruz-Acuna R, Resnick-Silverman L, Peura J, Lu C, Hasson D, Klein-Szanto AJ, Taylor AM, Manfredi JJ, et al. p53 gain-of-function mutation induces metastasis via Brd4-dependent Csf-1 expression. Cancer Discovery. PMID 37676642 DOI: 10.1158/2159-8290.CD-23-0601 |
0.411 |
|
| 2023 |
Su Z, Kon N, Yi J, Zhao H, Zhang W, Tang Q, Li H, Kobayashi H, Li Z, Duan S, Liu Y, Olive KP, Zhang Z, Honig B, Manfredi JJ, et al. Specific regulation of BACH1 by the hotspot mutant p53 reveals a distinct gain-of-function mechanism. Nature Cancer. PMID 36973430 DOI: 10.1038/s43018-023-00532-z |
0.631 |
|
| 2023 |
Resnick-Silverman L, Zhou R, Campbell MJ, Leibling I, Parsons R, Manfredi JJ. In vivo RNA-seq and ChIP-seq analyses show an obligatory role for the C terminus of p53 in conferring tissue-specific radiation sensitivity. Cell Reports. 42: 112216. PMID 36924496 DOI: 10.1016/j.celrep.2023.112216 |
0.423 |
|
| 2021 |
Tong DR, Zhou W, Katz C, Regunath K, Venkatesh D, Ihuegbu C, Manfredi JJ, Laptenko O, Prives C. p53 frameshift mutations couple loss-of-function with unique neomorphic activities. Molecular Cancer Research : McR. PMID 34045312 DOI: 10.1158/1541-7786.MCR-20-0691 |
0.512 |
|
| 2021 |
Manfredi JJ. Mdm2 and MdmX: Partners in p53 Destruction. Cancer Research. 81: 1633-1634. PMID 34003788 DOI: 10.1158/0008-5472.CAN-21-0145 |
0.54 |
|
| 2021 |
Farkas M, Hashimoto H, Bi Y, Davuluri RV, Resnick-Silverman L, Manfredi JJ, Debler EW, McMahon SB. Distinct mechanisms control genome recognition by p53 at its target genes linked to different cell fates. Nature Communications. 12: 484. PMID 33473123 DOI: 10.1038/s41467-020-20783-z |
0.502 |
|
| 2020 |
Kon N, Churchill M, Li H, Mukherjee S, Manfredi JJ, Gu W. Robust p53 stabilization is dispensable for its activation and tumor suppressor function. Cancer Research. PMID 33323382 DOI: 10.1158/0008-5472.CAN-20-1804 |
0.534 |
|
| 2019 |
Manfredi JJ. p53 defies convention again: a p53 mutant that has lost tumor suppression but still can kill. The Embo Journal. e103322. PMID 31553097 DOI: 10.15252/Embj.2019103322 |
0.624 |
|
| 2019 |
Manfredi JJ. Inactivation of Wild-Type p53 by Asparagine Endopeptidase in Glioblastoma: An Opportunity to Target the "Undruggable". Journal of the National Cancer Institute. PMID 31400198 DOI: 10.1093/Jnci/Djz156 |
0.494 |
|
| 2019 |
Manfredi JJ. p53 and Development: Shedding Light on an Evolutionary Enigma. Developmental Cell. 50: 128-129. PMID 31336095 DOI: 10.1016/J.Devcel.2019.07.004 |
0.527 |
|
| 2019 |
Vadnais C, Chen R, Fraszczak J, Hamard PJ, Manfredi JJ, Möröy T. A novel regulatory circuit between p53 and GFI1 controls induction of apoptosis in T cells. Scientific Reports. 9: 6304. PMID 31004086 DOI: 10.1038/S41598-019-41684-2 |
0.668 |
|
| 2017 |
Giono LE, Resnick-Silverman L, Carvajal LA, St Clair S, Manfredi JJ. Mdm2 promotes Cdc25C protein degradation and delays cell cycle progression through the G2/M phase. Oncogene. PMID 28806397 DOI: 10.1038/Onc.2017.254 |
0.834 |
|
| 2017 |
Senturk JC, Bohlman S, Manfredi JJ. Mdm2 selectively suppresses DNA damage arising from inhibition of topoisomerase II independent of p53. Oncogene. 36: 6085-6096. PMID 28692049 DOI: 10.1038/Onc.2017.229 |
0.539 |
|
| 2017 |
Pappas K, Xu J, Zairis S, Resnick-Silverman L, Abate F, Steinbach N, Ozturk S, Saal LH, Su T, Cheung P, Schmidt H, Aaronson SA, Hibshoosh H, Manfredi JJ, Rabadan R, et al. p53 maintains baseline expression of multiple tumor suppressor genes. Molecular Cancer Research : McR. PMID 28483946 DOI: 10.1158/1541-7786.Mcr-17-0089 |
0.594 |
|
| 2017 |
Manfredi JJ. Tumor suppression by p53 involves inhibiting an enabler, FGF13. Proceedings of the National Academy of Sciences of the United States of America. PMID 28082725 DOI: 10.1073/Pnas.1619815114 |
0.488 |
|
| 2016 |
Bohlman S, Manfredi JJ. Mdm2-RNA Interactions as a Target for Cancer Therapy: It's Not All About p53. Cancer Cell. 30: 513-514. PMID 27728801 DOI: 10.1016/J.Ccell.2016.09.017 |
0.476 |
|
| 2016 |
Laptenko O, Tong DR, Manfredi J, Prives C. The Tail That Wags the Dog: How the Disordered C-Terminal Domain Controls the Transcriptional Activities of the p53 Tumor-Suppressor Protein. Trends in Biochemical Sciences. PMID 27669647 DOI: 10.1016/J.Tibs.2016.08.011 |
0.642 |
|
| 2016 |
Monteith JA, Mellert H, Sammons MA, Kuswanto LA, Sykes SM, Resnick-Silverman L, Manfredi JJ, Berger SL, McMahon SB. A rare DNA contact mutation in cancer confers p53 gain-of-function and tumor cell survival via TNFAIP8 induction. Molecular Oncology. PMID 27341992 DOI: 10.1016/J.Molonc.2016.05.007 |
0.605 |
|
| 2016 |
Barthelery NJ, Manfredi JJ. Cerebellum Development and Tumorigenesis: A p53-Centric Perspective. Trends in Molecular Medicine. 22: 404-13. PMID 27085812 DOI: 10.1016/J.Molmed.2016.03.006 |
0.65 |
|
| 2016 |
Mungamuri SK, Qiao RF, Yao S, Manfredi JJ, Gu W, Aaronson SA. USP7 Enforces Heterochromatinization of p53 Target Promoters by Protecting SUV39H1 from MDM2-Mediated Degradation. Cell Reports. PMID 26971997 DOI: 10.1016/J.Celrep.2016.02.049 |
0.68 |
|
| 2016 |
Li T, Liu X, Jiang L, Manfredi J, Zha S, Gu W. Loss of p53-mediated cell-cycle arrest, senescence and apoptosis promotes genomic instability and premature aging. Oncotarget. PMID 26943586 DOI: 10.18632/Oncotarget.7864 |
0.568 |
|
| 2016 |
Lee CC, Manfredi J. Abstract 3688: The C-terminal domain of tumor-derived mutant p53 is required for its oncogenic gain-of-function activity Cancer Research. 76: 3688-3688. DOI: 10.1158/1538-7445.Am2016-3688 |
0.63 |
|
| 2015 |
Resnick-Silverman L, Manfredi JJ. Two Faces of SIVA. Cancer Discovery. 5: 581-3. PMID 26037915 DOI: 10.1158/2159-8290.Cd-15-0484 |
0.498 |
|
| 2015 |
Laptenko O, Shiff I, Freed-Pastor W, Zupnick A, Mattia M, Freulich E, Shamir I, Kadouri N, Kahan T, Manfredi J, Simon I, Prives C. The p53 C terminus controls site-specific DNA binding and promotes structural changes within the central DNA binding domain. Molecular Cell. 57: 1034-46. PMID 25794615 DOI: 10.1016/J.Molcel.2015.02.015 |
0.527 |
|
| 2015 |
Lukin DJ, Carvajal LA, Liu WJ, Resnick-Silverman L, Manfredi JJ. p53 Promotes cell survival due to the reversibility of its cell-cycle checkpoints. Molecular Cancer Research : McR. 13: 16-28. PMID 25158956 DOI: 10.1158/1541-7786.Mcr-14-0177 |
0.836 |
|
| 2015 |
Mungamuri SK, Wang S, Manfredi JJ, Gu W, Aaronson SA. Ash2L enables P53-dependent apoptosis by favoring stable transcription pre-initiation complex formation on its pro-apoptotic target promoters. Oncogene. 34: 2461-70. PMID 25023704 DOI: 10.1038/Onc.2014.198 |
0.636 |
|
| 2015 |
Mungamuri SK, Qiao RF, Yao S, Manfredi JJ, Gu W, Aaronson SA. USP7 Enforces Heterochromatinization of p53 Target Promoters by Protecting SUV39H1 from MDM2-Mediated Degradation Cell Reports. DOI: 10.1016/j.celrep.2016.02.049 |
0.495 |
|
| 2014 |
Bohlman S, Manfredi JJ. p53-independent effects of Mdm2. Sub-Cellular Biochemistry. 85: 235-46. PMID 25201198 DOI: 10.1007/978-94-017-9211-0_13 |
0.669 |
|
| 2014 |
Benson EK, Mungamuri SK, Attie O, Kracikova M, Sachidanandam R, Manfredi JJ, Aaronson SA. p53-dependent gene repression through p21 is mediated by recruitment of E2F4 repression complexes. Oncogene. 33: 3959-69. PMID 24096481 DOI: 10.1038/Onc.2013.378 |
0.708 |
|
| 2013 |
Hamard PJ, Barthelery N, Hogstad B, Mungamuri SK, Tonnessen CA, Carvajal LA, Senturk E, Gillespie V, Aaronson SA, Merad M, Manfredi JJ. The C terminus of p53 regulates gene expression by multiple mechanisms in a target- and tissue-specific manner in vivo. Genes & Development. 27: 1868-85. PMID 24013501 DOI: 10.1101/Gad.224386.113 |
0.784 |
|
| 2013 |
Carvajal LA, Manfredi JJ. Another fork in the road--life or death decisions by the tumour suppressor p53. Embo Reports. 14: 414-21. PMID 23588418 DOI: 10.1038/Embor.2013.25 |
0.833 |
|
| 2013 |
Senturk E, Manfredi JJ. Determine the effect of p53 on chemosensitivity. Methods in Molecular Biology (Clifton, N.J.). 962: 113-25. PMID 23150441 DOI: 10.1007/978-1-62703-236-0_9 |
0.576 |
|
| 2013 |
Senturk E, Manfredi JJ. p53 and cell cycle effects after DNA damage. Methods in Molecular Biology (Clifton, N.J.). 962: 49-61. PMID 23150436 DOI: 10.1007/978-1-62703-236-0_4 |
0.423 |
|
| 2013 |
Lee CC, Manfredi J. Abstract 5094: Investigating the role of CDC25B in inhibition of cellular proliferation Cancer Research. 74: 5094-5094. DOI: 10.1158/1538-7445.Am2014-5094 |
0.37 |
|
| 2012 |
Senturk E, Manfredi JJ. Mdm2 and tumorigenesis: evolving theories and unsolved mysteries. Genes & Cancer. 3: 192-8. PMID 23150752 DOI: 10.1177/1947601912457368 |
0.694 |
|
| 2012 |
Carvajal LA, Hamard PJ, Tonnessen C, Manfredi JJ. E2F7, a novel target, is up-regulated by p53 and mediates DNA damage-dependent transcriptional repression. Genes & Development. 26: 1533-45. PMID 22802528 DOI: 10.1101/Gad.184911.111 |
0.8 |
|
| 2012 |
Hamard PJ, Lukin DJ, Manfredi JJ. p53 basic C terminus regulates p53 functions through DNA binding modulation of subset of target genes. The Journal of Biological Chemistry. 287: 22397-407. PMID 22514277 DOI: 10.1074/Jbc.M111.331298 |
0.795 |
|
| 2012 |
Livesey KM, Kang R, Vernon P, Buchser W, Loughran P, Watkins SC, Zhang L, Manfredi JJ, Zeh HJ, Li L, Lotze MT, Tang D. p53/HMGB1 complexes regulate autophagy and apoptosis. Cancer Research. 72: 1996-2005. PMID 22345153 DOI: 10.1158/0008-5472.Can-11-2291 |
0.599 |
|
| 2012 |
Hamard PJ, Manfredi JJ. Mdm2's dilemma: to degrade or to translate p53? Cancer Cell. 21: 3-5. PMID 22264782 DOI: 10.1016/J.Ccr.2011.12.018 |
0.638 |
|
| 2012 |
Manfredi JJ. The p53 Tumor Suppressor Pathway in Tumorigenesis and Therapy Aacr Education Book. 2012: 165-169. DOI: 10.1158/AACR.EDB-12-6392 |
0.377 |
|
| 2011 |
Resnick-Silverman L, Manfredi JJ. Analyzing p53 regulated DNA damage checkpoints by flow cytometry. Methods in Molecular Biology (Clifton, N.J.). 782: 193-203. PMID 21870293 DOI: 10.1007/978-1-61779-273-1_14 |
0.404 |
|
| 2011 |
Chander H, Halpern M, Resnick-Silverman L, Manfredi JJ, Germain D. Skp2B overexpression alters a prohibitin-p53 axis and the transcription of PAPP-A, the protease of insulin-like growth factor binding protein 4. Plos One. 6: e22456. PMID 21829624 DOI: 10.1371/Journal.Pone.0022456 |
0.475 |
|
| 2010 |
Manfredi JJ. An identity crisis for a cancer gene: subcellular location determines ASPP1 function. Cancer Cell. 18: 409-10. PMID 21075306 DOI: 10.1016/J.Ccr.2010.11.003 |
0.381 |
|
| 2010 |
Manfredi JJ. The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor. Genes & Development. 24: 1580-9. PMID 20679392 DOI: 10.1101/Gad.1941710 |
0.62 |
|
| 2010 |
Chander H, Halpern M, Resnick-Silverman L, Manfredi JJ, Germain D. Skp2B attenuates p53 function by inhibiting prohibitin. Embo Reports. 11: 220-5. PMID 20134482 DOI: 10.1038/Embor.2010.2 |
0.643 |
|
| 2009 |
Manfredi JJ. Insights from a novel p53 isoform in zebrafish want to reel us in, but will we take the bait? Genes & Development. 23: 261-4. PMID 19204113 DOI: 10.1101/Gad.1778309 |
0.676 |
|
| 2009 |
Varmeh S, Manfredi JJ. Inappropriate activation of cyclin-dependent kinases by the phosphatase Cdc25b results in premature mitotic entry and triggers a p53-dependent checkpoint. The Journal of Biological Chemistry. 284: 9475-88. PMID 19136558 DOI: 10.1074/jbc.M900037200 |
0.533 |
|
| 2009 |
Zhao B, Benson EK, Qiao R, Wang X, Kim S, Manfredi JJ, Lee SW, Aaronson SA. Cellular senescence and organismal ageing in the absence of p21(CIP1/WAF1) in ku80(-/-) mice. Embo Reports. 10: 71-8. PMID 19079133 DOI: 10.1038/Embor.2008.220 |
0.508 |
|
| 2008 |
Varmeh S, Manfredi JJ. Overexpression of the dual specificity phosphatase, Cdc25C, confers sensitivity on tumor cells to doxorubicin-induced cell death. Molecular Cancer Therapeutics. 7: 3789-99. PMID 19074854 DOI: 10.1158/1535-7163.MCT-08-0838 |
0.343 |
|
| 2007 |
Giono LE, Manfredi JJ. Mdm2 plays a positive role as an effector of p53-dependent responses. Cell Cycle (Georgetown, Tex.). 6: 2143-7. PMID 17786043 DOI: 10.4161/Cc.6.17.4647 |
0.839 |
|
| 2007 |
Giono LE, Manfredi JJ. Mdm2 is required for inhibition of Cdk2 activity by p21, thereby contributing to p53-dependent cell cycle arrest. Molecular and Cellular Biology. 27: 4166-78. PMID 17371838 DOI: 10.1128/Mcb.01967-06 |
0.856 |
|
| 2006 |
Giono LE, Manfredi JJ. The p53 tumor suppressor participates in multiple cell cycle checkpoints. Journal of Cellular Physiology. 209: 13-20. PMID 16741928 DOI: 10.1002/Jcp.20689 |
0.775 |
|
| 2006 |
Resnick-Silverman L, Manfredi JJ. Gene-specific mechanisms of p53 transcriptional control and prospects for cancer therapy. Journal of Cellular Biochemistry. 99: 679-89. PMID 16676359 DOI: 10.1002/Jcb.20925 |
0.644 |
|
| 2006 |
St Clair S, Manfredi JJ. The dual specificity phosphatase Cdc25C is a direct target for transcriptional repression by the tumor suppressor p53. Cell Cycle (Georgetown, Tex.). 5: 709-13. PMID 16582636 DOI: 10.4161/Cc.5.7.2628 |
0.663 |
|
| 2006 |
Zhang XH, Zhao C, Seleznev K, Song K, Manfredi JJ, Ma ZA. Disruption of G1-phase phospholipid turnover by inhibition of Ca2+-independent phospholipase A2 induces a p53-dependent cell-cycle arrest in G1 phase. Journal of Cell Science. 119: 1005-15. PMID 16492706 DOI: 10.1242/jcs.02821 |
0.372 |
|
| 2006 |
Sachchidanand, Resnick-Silverman L, Yan S, Mutjaba S, Liu WJ, Zeng L, Manfredi JJ, Zhou MM. Target structure-based discovery of small molecules that block human p53 and CREB binding protein association. Chemistry & Biology. 13: 81-90. PMID 16426974 DOI: 10.1016/J.Chembiol.2005.10.014 |
0.649 |
|
| 2005 |
Prives C, Manfredi JJ. The continuing saga of p53--more sleepless nights ahead. Molecular Cell. 19: 719-21. PMID 16168367 DOI: 10.1016/J.Molcel.2005.08.024 |
0.616 |
|
| 2005 |
Manfredi JJ, Dong J, Liu WJ, Resnick-Silverman L, Qiao R, Chahinian P, Saric M, Gibbs AR, Phillips JI, Murray J, Axten CW, Nolan RP, Aaronson SA. Evidence against a role for SV40 in human mesothelioma. Cancer Research. 65: 2602-9. PMID 15805256 DOI: 10.1158/0008-5472.Can-04-2461 |
0.4 |
|
| 2004 |
St Clair S, Giono L, Varmeh-Ziaie S, Resnick-Silverman L, Liu WJ, Padi A, Dastidar J, DaCosta A, Mattia M, Manfredi JJ. DNA damage-induced downregulation of Cdc25C is mediated by p53 via two independent mechanisms: one involves direct binding to the cdc25C promoter. Molecular Cell. 16: 725-36. PMID 15574328 DOI: 10.1016/J.Molcel.2004.11.002 |
0.868 |
|
| 2003 |
Thornborrow EC, Maurer M, Manfredi JJ. Electrophoretic mobility shift analysis of the DNA binding of tumor suppressor gene products. Methods in Molecular Biology (Clifton, N.J.). 223: 87-100. PMID 12777722 DOI: 10.1385/1-59259-329-1:87 |
0.757 |
|
| 2003 |
Manfredi JJ. p53 and apoptosis: it's not just in the nucleus anymore. Molecular Cell. 11: 552-4. PMID 12667439 DOI: 10.1016/S1097-2765(03)00106-0 |
0.594 |
|
| 2002 |
Thornborrow EC, Patel S, Mastropietro AE, Schwartzfarb EM, Manfredi JJ. A conserved intronic response element mediates direct p53-dependent transcriptional activation of both the human and murine bax genes. Oncogene. 21: 990-9. PMID 11850816 DOI: 10.1038/Sj.Onc.1205069 |
0.844 |
|
| 2002 |
Bargonetti J, Manfredi JJ. Multiple roles of the tumor suppressor p53. Current Opinion in Oncology. 14: 86-91. PMID 11790986 DOI: 10.1097/00001622-200201000-00015 |
0.567 |
|
| 2001 |
Thornborrow EC, Manfredi JJ. The tumor suppressor protein p53 requires a cofactor to activate transcriptionally the human BAX promoter. The Journal of Biological Chemistry. 276: 15598-608. PMID 11278953 DOI: 10.1074/Jbc.M011643200 |
0.834 |
|
| 2001 |
Buschmann T, Lin Y, Aithmitti N, Fuchs SY, Lu H, Resnick-Silverman L, Manfredi JJ, Ronai Z, Wu X. Stabilization and activation of p53 by the coactivator protein TAFII31. The Journal of Biological Chemistry. 276: 13852-7. PMID 11278372 DOI: 10.1074/Jbc.M007955200 |
0.661 |
|
| 2000 |
Houvras Y, Benezra M, Zhang H, Manfredi JJ, Weber BL, Licht JD. BRCA1 physically and functionally interacts with ATF1. The Journal of Biological Chemistry. 275: 36230-7. PMID 10945975 DOI: 10.1074/Jbc.M002539200 |
0.355 |
|
| 1999 |
Thornborrow EC, Manfredi JJ. One mechanism for cell type-specific regulation of the bax promoter by the tumor suppressor p53 is dictated by the p53 response element. The Journal of Biological Chemistry. 274: 33747-56. PMID 10559267 DOI: 10.1074/Jbc.274.47.33747 |
0.853 |
|
| 1998 |
Tang HY, Zhao K, Pizzolato JF, Fonarev M, Langer JC, Manfredi JJ. Constitutive expression of the cyclin-dependent kinase inhibitor p21 is transcriptionally regulated by the tumor suppressor protein p53. The Journal of Biological Chemistry. 273: 29156-63. PMID 9786925 DOI: 10.1074/Jbc.273.44.29156 |
0.728 |
|
| 1998 |
Resnick-Silverman L, St Clair S, Maurer M, Zhao K, Manfredi JJ. Identification of a novel class of genomic DNA-binding sites suggests a mechanism for selectivity in target gene activation by the tumor suppressor protein p53. Genes & Development. 12: 2102-7. PMID 9679054 DOI: 10.1101/Gad.12.14.2102 |
0.64 |
|
| 1993 |
Bargonetti J, Manfredi JJ, Chen X, Marshak DR, Prives C. A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein Genes and Development. 7: 2565-2574. PMID 8276239 DOI: 10.1101/Gad.7.12B.2565 |
0.543 |
|
| 1993 |
Prives C, Manfredi JJ. The p53 tumor suppressor protein: meeting review. Genes & Development. 7: 529-534. PMID 8096197 DOI: 10.1101/Gad.7.4.529 |
0.49 |
|
| 1991 |
Prives C, Bargonetti J, Friedman PN, Manfredi JJ, Wang EH. Functional consequences of the interactions of the p53 tumor suppressor protein and SV40 large tumor antigen Cold Spring Harbor Symposia On Quantitative Biology. 56: 227-235. PMID 1668081 DOI: 10.1101/Sqb.1991.056.01.028 |
0.425 |
|
| Show low-probability matches. |